Great Lakes Advisors LLC Has $13.69 Million Holdings in Zoetis Inc. (NYSE:ZTS)
Great Lakes Advisors LLC lowered its stake in shares of Zoetis Inc. (NYSE:ZTS) by 8.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 82,741 shares of the company’s stock after selling 8,118 shares during the period. Great Lakes Advisors LLC’s holdings in Zoetis were worth $13,694,000 as of its most recent SEC filing.
Other hedge funds also recently added to or reduced their stakes in the company. Jeppson Wealth Management LLC bought a new position in shares of Zoetis in the third quarter valued at approximately $25,000. Graves Light Private Wealth Management Inc. purchased a new stake in Zoetis in the 4th quarter valued at $31,000. Arlington Partners LLC bought a new position in Zoetis during the 4th quarter valued at $32,000. Hoover Financial Advisors Inc. bought a new stake in shares of Zoetis in the 4th quarter worth $32,000. Finally, Trustcore Financial Services LLC raised its holdings in shares of Zoetis by 143.5% in the fourth quarter. Trustcore Financial Services LLC now owns 207 shares of the company’s stock valued at $34,000 after purchasing an additional 122 shares during the last quarter. Institutional investors and hedge funds own 92.50% of the company’s stock.
Several research firms have commented on ZTS. Morgan Stanley increased their price objective on shares of Zoetis from $167.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, November 13th. Truist increased their price target on Zoetis from $160.00 to $170.00 in a research report on Thursday, November 12th. Credit Suisse Group boosted their price objective on Zoetis from $197.00 to $203.00 in a research report on Wednesday, February 17th. Finally, Barclays raised their target price on Zoetis from $175.00 to $189.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Zoetis currently has a consensus rating of “Buy” and a consensus price target of $167.25.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, February 16th. The company reported $0.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.86 by $0.05. Zoetis had a net margin of 25.50% and a return on equity of 63.89%. During the same quarter in the previous year, the company posted $0.92 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post 3.63 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 1st. Stockholders of record on Wednesday, April 21st will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Tuesday, April 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 0.62%. Zoetis’s dividend payout ratio (DPR) is currently 27.47%.
In other Zoetis news, CEO Kristin C. Peck sold 10,500 shares of the stock in a transaction on Wednesday, November 25th. The shares were sold at an average price of $161.51, for a total transaction of $1,695,855.00. Following the completion of the sale, the chief executive officer now owns 38,374 shares of the company’s stock, valued at approximately $6,197,784.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Heidi C. Chen sold 1,180 shares of the firm’s stock in a transaction on Tuesday, December 1st. The stock was sold at an average price of $161.64, for a total transaction of $190,735.20. Following the completion of the sale, the executive vice president now directly owns 17,515 shares in the company, valued at approximately $2,831,124.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 13,734 shares of company stock worth $2,217,592. Company insiders own 0.17% of the company’s stock.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Featured Story: Day Trading
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.